Recent research has indicated that PCSK9 inhibitors can mitigate brain pathologies, such as vascular events in stroke (Castilla-Guerra, Fernandez-Moreno & Rico-Corral, 2019), prevent brain injury resulting from myocardial ischemia/reperfusion damage (Apaijai et al., 2019), and reduce insulin resistance-related cognitive impairment (Arunsak et al., 2020). This evidence concerns the gene PCSK9 and Stroke.